Evidence – Predicting Safety & Clinical Outcomes Using Preclinical Tumour & Normal Tissue Models with T-Cell Engagers

• In vitro approaches to assess safety and efficacy of T cell engagers
• Understanding the opportunities and limitations of current in vitro and in vivo systems in predicting unwanted side effects
• Exploring emerging approaches to improve safety assessment in early drug development

Speakers:

Andrew Whale

Director - Nonclinical Safety

Immunocore Ltd